Year: 2024

Progress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2 Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA) Clinical update on OCU410ST Phase 1/2 GARDian clinical trial for Stargardt disease Featuring patients, investigators and thought leadersMALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an in-person Clinical Showcase on Tuesday, November 12, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq MarketSite in Times Square, New York City. The event will focus on encouraging updates from...

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.S., as chief medical officer, Terry Evans as chief commercial officer and Christiana Cioffi, MBA, as chief strategy officer, all of which become effective immediately. “Building an experienced, multi-talented executive leadership team is a critical step for Fennec as we embark on a new chapter in the organization’s evolution, and I am delighted to welcome Pierre, Terry and...

MONTREAL, Oct. 28, 2024 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V:FPC) (“Falco” or the “Corporation”) is pleased to provide a corporate update on its flagship Horne 5 Project located in Rouyn-Noranda, Québec (the “Falco Horne 5 Project” or the “Project”). Following the completion of the public hearing process with the Office of Public Hearings on the Environment (“BAPE”), Falco continues to file documentation and provide responses to the BAPE, in view of the completion of its report, which is due for submission to the Minister of the Environment, the Fight Against Climate Change, Wildlife and Parks by December 26, 2024. Also, with the continued strength in gold and copper, Falco will work towards updating the 2021 Feasibility Study, which utilized a gold price of US$1,600 and a copper price of US$3.25/lb, with targeted completion...

BOCA RATON, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) (“ADT” or the “Company”) today announced a proposed secondary public offering of 56,000,000 shares of the Company’s common stock held by certain entities managed by affiliates of Apollo Global Management, Inc. (the “Selling Stockholders”). The underwriters will have a 30-day option to purchase up to an additional 8,400,000 shares of common stock from the Selling Stockholders. The Company is not selling any shares and will not receive any proceeds from the proposed offering. In addition, ADT has authorized the concurrent purchase from the underwriters of 16,000,000 shares of common stock as part of the secondary public offering (the “Share Repurchase”) subject to the completion of the offering. The Share Repurchase is part of the Company’s existing $350 million...

TEL AVIV, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) — Enlight Renewable Energy (“Enlight”, NASDAQ: ENLT, TASE: ENLT.TA), a leading global renewable energy platform, today announced it will release its financial results for the third quarter ended September 30, 2024, before market open on Wednesday, November 13, 2024. Conference Call Information Enlight will host a conference call to review its financial results and business outlook at 8:00 AM ET on Wednesday, November 13, 2024. Management will deliver prepared remarks followed by a question-and-answer session. Participants can join by conference call or webcast: Conference Call Please pre-register to join by conference call: https://register.vevent.com/register/BI281173453e3b42cdad641356114470c6Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. Webcast Please...

CHICAGO, Oct. 28, 2024 (GLOBE NEWSWIRE) — Marquette National Corporation (OTCQX: MNAT) today reported year-to-date net income of $14.2 million compared to net income of $12.3 million for the first nine months of 2023. Earnings per share for the first nine months of 2024 were $3.25, as compared to earnings of $2.81 per share for the comparable period in 2023. At September 30, 2024, total assets were $2.199 billion, an increase of $57 million, or 3%, compared to $2.142 billion at December 31, 2023. Total loans decreased by $19 million to $1.391 billion compared to $1.410 billion at the end of 2023. Total deposits increased by $14 million, or 1%, to $1.724 billion compared to $1.710 billion at the end of 2023. Paul M. McCarthy, Chairman & CEO, said, “the primary reason for the increase in consolidated earnings was a higher level...

Net Income of $1.90 Million in the September 2024 Quarter, Down 3% from the Sequential Quarter and Up 8% from the Comparable Quarter Last Year Net Interest Margin of 2.84% in the September 2024 Quarter, Up 10 Basis Points from the Sequential Quarter and Down Four Basis Points from the Comparable Quarter Last Year Loans Held for Investment of $1.05 Billion at September 30, 2024, Unchanged from June 30, 2024 Total Deposits of $863.9 Million at September 30, 2024, Down 3% from June 30, 2024 Non-Performing Assets to Total Assets Ratio of 0.17% at September 30, 2024, Improved from 0.20% at June 30, 2024 Non-Interest Expenses Remain Well Controlled RIVERSIDE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — October 28, 2024 – Provident Financial Holdings, Inc. (“Company”), NASDAQ GS: PROV, the holding company for Provident Savings Bank, F.S.B....

Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the “Record Date”) for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex. Based on independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. (“Semnur”) is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102. Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) by the end of October 2024 for the previously announced proposed business combination...

SINGAPORE, Oct. 28, 2024 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (“UP Fintech” or the “Company”) (NASDAQ: TIGR), a leading online brokerage firm focusing on global investors, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the U.S. market opens on November 12, 2024. UP Fintech’s management will hold an earnings conference call at 8:00 AM on November 12, 2024, U.S. Eastern Time (9:00 PM on November 12, 2024, Singapore/Hong Kong Time). Conference Call Information: All participants wishing to attend the call must preregister online before they may receive the dial-in numbers. Preregistration may require a few minutes to complete. Preregistration Information: Please note that all participants will need to pre-register for the conference call, using the link:  https://register.vevent.com/register/BI98badd2259764082bdf9df7a4e175bd8 It...

ArcelorMittal (‘the Company’) today announces the publication of its third quarter 2024 sell-side analyst consensus figures. The consensus figures are based on analysts’ estimates recorded on an external web-based tool provided and managed by an independent company, Visible Alpha. To arrive at the consensus figures below, Visible Alpha has aggregated the expectations of sell-side analysts who, to the best of our knowledge, cover ArcelorMittal on a continuous basis. This is currently a group of approximately 15 brokers. The listed sell-side analysts follow ArcelorMittal on their own initiative and ArcelorMittal is not responsible for their views. ArcelorMittal is neither involved in the collection of the information nor in the compilation of the estimates. 3Q’24 consensus estimates*:EBITDA ($m)                         $1,488                         Net...